Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P05231
UPID:
IL6_HUMAN
Alternative names:
B-cell stimulatory factor 2; CTL differentiation factor; Hybridoma growth factor; Interferon beta-2
Alternative UPACC:
P05231; Q9UCU2; Q9UCU3; Q9UCU4
Background:
Interleukin-6 (IL-6), known by alternative names such as B-cell stimulatory factor 2 and Interferon beta-2, plays a pivotal role in immunity, tissue regeneration, and metabolism. It operates through binding to IL6R and IL6ST/gp130, initiating various signaling pathways crucial for biological functions including the acute phase response, differentiation of B and T cells, bone homeostasis, and metabolic control.
Therapeutic significance:
IL-6's involvement in diseases like Rheumatoid arthritis systemic juvenile highlights its dual role in both host defense and disease pathology. Its excessive synthesis is linked to severe complications, making it a target for therapeutic strategies aiming to modulate its activity for treating inflammatory disorders and potentially other IL-6 related conditions.